Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF regimen) in patients with metastatic colorectal cancer: The southern Italy cooperative oncology group experience

Clinical Colorectal Cancer

Volumn 10, Issue 1, 2011, Pages 42-47

  Comella, Pasquale ^a   Massidda, Bruno ^b   Natale, Donato ^c   Putzu, Carlo ^d   Sandomenico, Claudia ^a   Filippelli, Gianfranco ^c   Palmeri, Sergio ^e   Condemi, Giovanni ^c   Vessia, Giacomo ^c   Barberis, Giuseppe ^f   Ionta, Maria Teresa ^b   Tafuto, Salvatore ^g   Barbato, Enrico ^h  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Department of Oncology   (Italy)

^d Università Degli Studi di Sabari   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f Villa Betania Hospital   (Italy)

^g City Hospital   (Italy)

^h City Hospital   (Italy)

Author keywords

Combination regimen; IRIFAFU

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR MARKER; VITAMIN B COMPLEX;

ADULT; AGED; ALOPECIA; ANEMIA; ARTERY THROMBOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PROTEINURIA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; VOMITING; COLORECTAL TUMOR; CONFIDENCE INTERVAL; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; ITALY; MIDDLE AGED; MORTALITY; RISK; SURVIVAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; ITALY; LEUCOVORIN; MALE; MIDDLE AGED; RISK; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VITAMIN B COMPLEX;

EID: 80053410666     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.3816/CCC.2011.n.006     Document Type: Article

References (24)

1. P Carmeliet, RK Jain Angiogenesis in cancer and other disease Nature 407 2000 249 257
2. DJ Hicklin, LM Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1 16
3. RT Tong, Y Boucher, SV Kozin et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 2004 3731 3736 (Pubitemid 38697278)
4. F Winkler, SV Kozin, RT Tong et al. Kinetics of vascular normalization by VEGFR2 blockade governs tumor response to radiation Cancer Cell 6 2004 553 563
5. H Wildiers, G Guetens, G De Boeck et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 Br J Cancer 88 2003 1979 1986 (Pubitemid 36829677)
6. NH Fernando, HI Hurwitz Targeted therapy of colorectal cancer: Clinical experience with bevacizumab Oncologist 9 suppl 1 2004 11 18 (Pubitemid 38747843)
7. H Hurwitz, L Fehrenbacher, W Novotny et al. Bevacizumab plus irinotecan, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
8. CS Fuchs, J Marshall, E Mitchell et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study J Clin Oncol 25 2007 4779 4786 (Pubitemid 350086481)
9. CS Fuchs, J Marshall, J Barrueco Randomized, controlled trial of irinotecan plus infusional, bolus, oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results From the BICC-C Study J Clin Oncol 26 2008 689 690 (Pubitemid 351264373)
10. LB Saltz, S Clarke, E Díaz-Rubio et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study J Clin Oncol 26 2008 2013 2019
11. P Comella, E Crucitta, F De Vita et al. Addition of either irinotecan or methotrexate to bolus fluorouracil and high-dose leucovorin every two weeks in advanced colorectal carcinoma: A randomized study of the Southern Italy Cooperative Oncology Group Ann Oncol 13 2002 866 873 (Pubitemid 34752681)
12. P Comella, B Massidda, G Filippelli et al. Oxaliplatin plus high dose folinic acid and 5-fluoruracil I.V. bolus (OXAFAFU) versus irinotecan plus high dose folinic acid and 5-fluoruracil I.V. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase III trial Ann Oncol 16 2005 878 886 (Pubitemid 40903912)
13. P Comella, B Massidda, G Filippelli et al. Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: Pooled analysis of two consecutive Southern Italy Cooperative Oncology Group trials Clin Colorectal Cancer 5 2005 203 210
14. P Comella, A Farris, V Lorusso et al. Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma Br J Cancer 89 2003 992 996 (Pubitemid 37239200)
15. P Therasse, SG Arbuck, EA Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
16. EL Kaplan, P Meier Non parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
17. R Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10 (Pubitemid 19099520)
18. Y Cao, A Tan, F Gao et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer Int J Colorectal Dis 24 2009 677 685
19. S Welch, K Spithoff, RB Rumble et al. The Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review Ann Oncol 21 2010 1152 1162
20. F Yuan, Y Chen, M Dellian et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody Proc Natl Acad Sci USA 93 1996 14765 14770 (Pubitemid 26419043)
21. MA Graham, GF Lockwood, D Greenslade et al. Clinical pharmacokinetics of oxaliplatin: A critical review Clin Cancer Res 6 2000 1205 1218 (Pubitemid 30226200)
22. A Sobrero, S Ackland, S Clarke et al. Phase IV Study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer Oncology 77 2009 113 119
23. A Grothey, MM Sugrue, DM Purdie et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
24. LM Ellis, DG Haller Bevacizumab beyond progression: Does this make sense? J Clin Oncol 26 2008 5313 5315